AI in Drug Development 2026: The Shift to Execution

On ths webinar Sara Mallatt, AlphaSense’s Director of Healthcare Research and Dr. Paul Agapow, former Director of Data Science at GSK, explored how AI is transforming medicine. They discussed whether AI is on track to make drug development faster, cheaper, and more successful.

Sara and Paul discussed:

• The "Autonomous Lab" Shift: How robotics and AI are closing the loop in R&D.
• Regulatory Evolution: Navigating the new global rules for AI-assisted approvals.
• The Major Strategic Moves: How dealmaking is redefining the competition between pharma giants and the new wave of "TechBios.”

Join us to discover what has changed in AI-led drug development in the last year, which breakthroughs actually matter, and what to watch for in the year ahead.